Association of arterial stiffness with cognition in patients with Lewy body disorder
Objective: We aimed to investigate the association between arterial stiffness and cognitive function in patients with Lewy body disorder (LBD), including Parkinson disease (PD) and…Striatal dopamine transporter abnormalities in pure autonomic failure and speculation about the relationship with Lewy bodies
Objective: To reveal dopamine transporter (DAT) abnormalities in pure autonomic failure (PAF) and speculate about the relationship with the Lewy body progression pathway. Background:…Characterization of Noncoding Variant(s) Driving Genome-Wide Association of the PARK10 Locus in Autopsy-Proven Parkinson Disease and Controls.
Objective: Confirm the PARK10 locus as a major GWAS locus in autopsy-confirmed (AC) PD and AC controls and identify potential noncoding variants driving the association. …Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease
Objective: In the present study, we tried to elucidate if the occipital hypometabolism detected by [(18) F]-fluoro-d-glucose (FDG) positron emission tomography (PET) scan in patients with idiopathic…The clinical characteristics of Lewy body disease showed autonomic failures preceding motor signs
Objective: There are few cases of Lewy body disease who have been initially diagnosed as pure autonomic failure(PAF), because they had only autonomic symptoms for…Utility of the Mayo sleep questionnaire in predicting final autopsy diagnosis of alpha-synucleinopathy
Objective: To ascertain the utility of the MSQ in predicting final autopsy diagnosis of an alpha-synuleinopathy. Background: Idiopathic REM sleep behavior disorder (iRBD) is a…Safety of nelotanserin in a randomized placebo-controlled phase 2 study
Objective: To explore the safety of nelotanserin in a phase 2 study in patients with nelotanserin. Background: Nelotanserin is a highly selective and poent inverse…Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia
Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.